English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Experimental work has shown that during the development of tumours,host macrophages can deactivate natural killer cells and suppress lymphokine-activated killer celldevelopment, apparently through prostaglandin E2 production. Continuous indomethacin combined withinterleukin (IL)-2 may totally eradicate experimental lung metastases. The preliminary results of a phaseII trial of this combination are reported. Indomethacin 50 to 75 mg tid and ranitidine 150 mg bid are startedat least one week before IL-2 and continued until disease progression. IL-2 is given by continuous infusionfor three courses, each consisting of five days of treatment and six days of rest. IL-2 starting dose is 3.0x106Cetus U/m2 for the first course with escalation to 4.5x106 and 6.0x106 U/m2 if toxicity allows. Pressoragents are not used. Thirty-two renal carcinoma patients were registered with seven withdrawing early.Two complete and three partial responses were seen for a response rate of (20%) for eligible and treatedpatients, or (16%) for all entered patients. Minor responses were seen in three patients. Twenty-fivemelanoma patients have been registered thus far and 18 have been eligible to proceed with IL-2 therapy.One complete and two partial responses have been seen. Two of these responses (one complete and onepartial) were achieved on indomethacin and ranitidine alone, before starting IL-2

Continuous Indomethacin and Ranitidine with Interleukin-2 in Advanced Renal Carcinoma and Melanoma: A Preliminary Report